About the Follicular Lymphoma Foundation

About the FLF

Nobody deserves to live with an incurable cancer. The Follicular Lymphoma Foundation (FLF) is dedicated to changing that. As the first charity focused solely on finding a cure for follicular lymphoma, we’re leading the charge to accelerate research and provide hope to patients worldwide.

With established entities in Israel, the United Kingdom, and the United States, we drive international collaboration to accelerate progress in the diagnosis, treatment, and eventual cure of this cancer.

Our worldwide reach allows us to partner with leading researchers, healthcare professionals, and patient communities across diverse regions, ensuring our efforts are targeted where they are needed most. 

Through our global partnerships and a unified approach, we are breaking down barriers in research and patient support. Join us in our mission to Unlock the Cure for follicular lymphoma.

What is FL?

Follicular lymphoma is a type of blood cancer affecting over a million people across the world. Follicular lymphoma is the 2nd most common non-Hodgkin lymphoma, yet despite its prevalence, most people have never heard of it. This means it’s not getting the scientific attention or the funding it deserves. We’re collaborating with global leaders in the industry to change this. 

Follicular lymphoma isn’t like most other cancers. For most people, it isn’t an aggressive disease. Instead, individuals with it will go through periods of active disease, followed by remissions. 

Living with follicular lymphoma causes a range of physical and emotional challenges, as well as living with the uncertainty of not knowing when and how the cancer will return.

Around a fifth of people living with follicular lymphoma will develop an acute form of the disease which can be highly resistant to treatment and have a poor outcome for patients.

Follicular lymphoma is currently incurable, but we are committed to changing that – for patients living with it now and for those who will be diagnosed in the future. With your help, a cure is just around the corner.

Our mission

To find a cure and find it fast

Follicular lymphoma is far from a new disease. But although first diagnosed almost a century ago in 1925, progress in the treatment of follicular lymphoma has been frustratingly slow. Too slow for people living with this condition. We’re not prepared to wait any longer.

Research and science have progressed rapidly – survival rates for some cancers have increased dramatically. Yet follicular lymphoma receives comparatively little funding and little attention – unless you know someone with FL you are unlikely to have heard of it. Nobody should live with an incurable cancer – when we can change that.

Follicular lymphoma

Our history

We know better than anyone what it’s like to live with follicular lymphoma. We understand the fear, the challenges, and the uncertainty an FL diagnosis and ongoing treatments bring. That’s because the Follicular Lymphoma Foundation was launched in the summer of 2019 by our founder, Nicola Mendelsohn, who was diagnosed with FL in November 2016.

At the time, despite being the second most common non-Hodgkin lymphoma, there was very little information available about follicular lymphoma. During her search to understand her condition better, Nicola connected with the ‘Living with Follicular Lymphoma’ Facebook group. Here she had the opportunity to be part of a community of others who shared her journey, and who

shared their own insight, advice and support. The group has over 12,000 members globally – a close-knit online community of people going through the same journeys.

Over time, Nicola became more involved in the stories and experiences of the individuals in the group as well as her own treatment. This led her to develop relationships with leading clinicians and investigators in the field, who convinced her that by raising awareness and funds, so much more could be done to find a cure.

Driven by her passion to make a difference to people living with follicular lymphoma and find a cure for this disease, the Follicular Lymphoma Foundation was established in the summer of 2019.

Our trustees

Nicola Mendelsohn, CBE – Chair

Nicola Mendelsohn is the Head of Global Business Group at Meta. She also serves on The Mayor of London’s Business Advisory Board, the UK government’s Industrial Strategy Council, and is a non-executive director of Diageo. Alongside her husband, she is co-president of the charity Norwood.

In 2015, Nicola was awarded a Commander of the British Empire (CBE) for services to the creative industries in the UK. Prior to joining Meta, she spent over 20 years in advertising, holding prominent roles such as Industry Chair of the UK Creative Industries Council, first female President of the IPA, Trustee of The White Ribbon Alliance, Chairman of Women’s Aid Development Board, and President of WACL. She was also a Director of the Women’s Prize for Fiction.

Her greatest joy in life comes from her husband, Jon, and their four children: Gabi, Danny, Sam, and Zac.

Jon Mendelsohn

Lord Mendelsohn brings a wealth of experience and a profound commitment to improving the lives of those affected by this challenging form of cancer.

With a background in politics and business, Lord Mendelsohn has held numerous leadership roles, leveraging his expertise to drive impactful initiatives and foster innovative solutions. His strategic vision and dedication have been instrumental in advancing the foundation’s mission to support research, provide patient resources, and advocate for better treatments.

Beyond his work with the Follicular Lymphoma Foundation, Lord Mendelsohn is an active member of the House of Lords, where he contributes to a wide array of policy discussions, particularly those related to healthcare and social justice. His passion for making a difference is evident in all his endeavors, making him a pivotal force in the fight against follicular lymphoma.

Richard Harrington

Richard is a distinguished Member of the House of Lords and served as the Member of Parliament for Watford from 2010 to 2019. He most recently held the position of Minister of State (Minister for Refugees) and has previously served in several key ministerial roles, including in the Home Office, Department for Work and Pensions, and the Department for Business, Energy & Industrial Strategy.

Before his political career, Richard spent 25 years in the hotel and real estate industries, focusing on large-scale property development and the sale and management of hotels. His extensive experience in these sectors includes significant trans-Atlantic boardroom involvement.

In addition to his professional achievements, Richard is deeply committed to philanthropy. He serves as a trustee of several charities, is a Patron of Peace Hospice Care, and is a former Fundraising Chairman of the Variety Club Children’s Society.

Andrea Wong

Andrea Wong serves on the boards of Liberty Media Corporation, Qurate Retail Group, Hudson’s Bay Company, Hudson Pacific Properties and Social Capital Hedosophia Holdings. She is also a Governor of the British Film Institute and a Trustee of the Royal Academy of Arts.

She was most recently President, International Production for Sony Pictures Television and President, International for Sony Pictures Entertainment based in London.

Previously, Wong served as President and CEO of Lifetime Networks. Prior to that, she was Executive Vice President of Alternative Programming, Specials and Late Night at ABC.

Wong graduated MIT with a degree in electrical engineering and received an MBA from Stanford University. She is also a Henry Crown Fellow at the Aspen Institute and a member of the Committee of 100.

Mike Thompson, MBE

Mike was CEO at the Association of the British Pharmaceutical Industry (ABPI) from 2016-19, representing the industry with Government, and at Select Committees, and in broadcast media. He had previously had a twenty-year career with GlaxoSmithKline as a senior Commercial leader working at the UK, European and Global level.

After Oxford he joined Unilever as a trainee and became a classically trained marketer working in food and personal products.

He has been on the Committee of The Wine Society, the world’s oldest wine ‘mutual’, for over twenty years, and was on the Board of London & Partners, the Mayor of London’s promotional agency for the city, through the Olympics in 2012.

Dr. Jonathan Simons

Jonathan is an American physician-scientist, medical oncologist, and biotechnology inventor. He is currently the Chief Science Officer and Medical Director of the Marcus Foundation and a renowned leader in prostate cancer research.

His groundbreaking work at Johns Hopkins University and Emory University has significantly advanced the understanding of cancer metastases and the role of immunomodulatory cytokines. Jonathan’s translational research proved the feasibility of overcoming immune tolerance in metastatic prostate cancer using GM-CSF gene transduced vaccines.

Jonathan was the Founding Director of Georgia’s first NCI-designated cancer center, the Winship Cancer Institute at Emory University, where he also served as Chief of Hematology and Oncology. Before Emory, he directed the Molecular Pharmacology Program at Johns Hopkins University.

He has held numerous leadership roles with organizations such as the American Cancer Society, American Association of Cancer Research, and the National Cancer Institute, contributing significantly to national cancer research and policy initiatives.

Jess Burley

Jess has been Executive Chair of mSix&Partners since January 2022, following 12 years as Global Chief Executive. She established the business as one of the fastest-growing media planning and buying agencies. As Executive Chair of mSix&Partners, Jess continues to advise a number of clients and is leading development of The&Academy.

With a career spanning advertising, marketing and publishing, Jess has a track record of growth, transformation and building winning teams. Prior to joining mSix&Partners, as Group Managing Direct Jess led the restructure of Natmags and Hearst Digital to address changing digital markets and audience trends. She also headed up the online division of Future Publishing.

She has held Non-Executive positions at Quarto Plc, UK Mail Plc, Jacques Vert Plc and TalkTalk Telecom Plc. She was a trustee of The Mix, the young person’s charity supporting 13-24 year olds. She continues to mentor colleagues at all levels at mSix&Partners.

Jess is driven by belief in the impact of collaboration aligned to a bold vision, with a healthy dose of passion and energy. Outside of work, she enjoys walking, cooking, golf and crime fiction.

Our team

Kate Rogers Chief Executive Officer

Kate Rogers joins from her previous role at GSK plc as Global Finance Transformation Lead at GSK. She also continues to serves as Non-Executive Director and Audit Committee Chair for Ixico Plc, a Medical Imaging company for Biopharmaceutical clinical research.

Previous to leading the recent transformation, Kate was CFO for Laboratoire Glaxo SmithKline SaS (GSK France) and has held senior finance, business transformation and leadership roles in GSK over a period of 20 years. Kate has a degree in Engineering Science from Oxford University and is a Chartered Management Accountant. After graduating from Oxford, Kate joined Unilever as a management trainee, where she developed her early career in commercial finance and change management. From Unilever, Kate joined the pharmaceutical and life sciences industry, and has a deep belief and passion for enabling scientific advances to improve human health.

Kate Rogers said “I am excited finally to join the FLF and am looking forward to making a difference in this disease, driving our ambitions and finding routes for transformative change in scientific research. I’ll be working tirelessly with the teams to progress the search for better treatments and secure a cure for FL patients, and I can’t wait to get started”
The FLF is dedicated to improving lives for the thousands living with FL today and for everyone who is diagnosed tomorrow.

Mitchell Smith, MD, PhD Chief Medical Officer

Dr Smith earned his Medical Degree and PhD at Case Western Reserve University School of Medicine, Cleveland, OH. He completed an internship in Internal Medicine at the Long Island Jewish Hospital, NY, spent 3 years as a Resident in Pathology at Washington University – Barnes Hospital, in St. Louis, MO, then another year as a Resident in Internal Medicine at the Jewish Hospital of St. Louis, MO. His Fellowship in Medical Oncology was at Memorial Sloan-Kettering Cancer Centre, NY where he also was a Fellow in Biomedical Research in the Clinical Scholars Program. He is Board-certified in Internal Medicine, Haematology and Medical Oncology.

Dr Smith’s experience is broad and spans a number of years. After serving as Assistant Professor in Medical Oncology at Wayne State University in Detroit, MI, he joined Fox Chase Cancer Centre in 1993, where he remained as Director of the Lymphoma Program and Professor of Medicine until 2012. He served as the Director of the Lymphoid Malignancy Program at the Cleveland Clinic, Cleveland, OH from 2012 to 2017, when he joined the GW Cancer Centre in Washington DC as Associate Cancer Centre Director for Clinical Investigations, as well as Chief of the Division of Oncology & Blood Disorders. His clinical and laboratory interests have focused on targeted approaches to improve therapy of lymphoid malignancies. He has been involved in numerous clinical trials of targeted therapies, including CART cells, in lymphoma, leukaemia and myeloma.

Dr Smith’s honours include a lifetime achievement award from the Delaware chapter of the LLS. He is an active member of the ASCO, AACR, ASH and ECOG. He has served on the NCCN lymphoma and myeloma guideline committees and chaired the Mantle Cell Lymphoma subcommittee of the NCTN lymphoma planning committee.

Maggie Bolger has joined the Follicular Lymphoma Foundation as the new Vice President of Fundraising Strategy and Operations.

Maggie brings over a decade of experience in development and fundraising, having led successful campaigns and major gift initiatives at prestigious organizations such as the Jane Goodall Institute, Oregon Health & Science University Foundation, and the Oregon Food Bank.

Her expertise in building robust fundraising infrastructures and securing significant contributions will be instrumental in advancing the FLF’s mission to find a cure for follicular lymphoma. Maggie is dedicated to driving the foundation’s strategic fundraising efforts, ensuring sustained growth and impactful donor engagement.

Dr Julie Dodds - Director of Patient and Clinical Research Programmes

Julie previously worked as a Senior Research Fellow at University College London (UCL), where she conducted sexual health research and obtained a PhD in HIV epidemiology.

In her last role she gained experience in grant development, large multi-centre clinical trials, individual participant data meta-analysis and linking with industry. Julie has a particular interest in Patient and Public Involvement in research and believes it is crucial to incorporate patient’s views and experiences into the research process. She assisted in the set-up of Katie’s Team, a patient and public involvement group for women’s health in East London.

Julie has joined the FLF Team to set-up the FLF’s research programme of work and leads on all the operational aspects of the foundation. She is advising on the structure of each programme area, establishing standard operating procedures and reporting metrics and supporting the development of new partnerships and is directly responsible for the FL Patient Recruitment and Engagement.

FLF fundraising manager Louise

Louise Blair joins us in a new role, as FLF Fundraising Manager. Lou is responsible for sustaining and building the UK fundraising pipeline of individual donors along with trusts and corporates.

Having spent her early career as an author of numerous health-based cookbook. Lou decided to make the move to fundraising within the charity sector, the thrill of making a difference for which ever cause she worked for continues to drive her enthusiasm and passion.

Lou has a wide and varied experience of Fundraising Management in NFP, gained from over 11 years in various roles for a number of different charities including MNDA, Diabetes UK and Woking and Sam Beare Hospice. Lou has a true desire to make the lives of those living with medical conditions the best they can be and is delighted to join the team of passionate individuals at FLF to help make that difference.

 

 
Dr Zoe Drymoussi Research Manager

Zoe’s background is in laboratory-based translational biomedical research, having previously worked at Boehringer Ingelheim in Vienna, Austria, the Cambridge Institute of Cancer Research UK and at the Centre for Cell Biology and Cutaneous Research Queen Mary University of London, as part of her PhD studies.

More recently, Zoe has worked for several years as a senior trials co-ordinator at the Centre for Women’s Health at Queen Mary University of London. In her last role, Zoe was closely involved with Katie’s Team (a women’s health patient and public involvement advisory group based in East London), ensuring women’s voices were represented in the research being carried out.

Zoe has joined the FLF team to support the development of the FLF research programme.

Fiona Rose Executive Administrator

Fiona has spent her career offering high level operational and administrative services across a variety of corporate and not for profit organisations. She is now at a stage where working towards a common goal that will have a positive impact on people’s health and lifestyle is far more motivating and rewarding than merely seeing an increase in profits.

Passionate about being a pro-active member of the marketing and communications team, and also providing support to the FLF Team in all aspects of admin, Fiona is excited and grateful for the opportunity to work within such an amazing charity, and finds everyone incredibly enthusiastic which is a breath of fresh air. 

“At last, my natural exuberance for even the most menial of tasks has found a place alongside a fantastically like-minded team. No one minds how excited I get about spreadsheets!”

 

 

Zubair Ali Finance Manager

Zubair is a highly experienced and qualified accountant with over 15 years of experience in finance. He has worked across various sectors, which has given him the ability to pick up the best and most efficient practices across different industries. Zubair is skilled in report building, budgeting, and forecasting, and is detailed oriented with creative problem-solving abilities. He is always striving for process improvement and ensuring the FLF adheres to important governance rules and financial procedures. Zubair is also passionate about using his expertise to support a great cause and thoroughly enjoys working within the charity sector.

Rosie Leggett Senior Individual Giving Manager

Rosie is the Head of Donor Engagement at the Follicular Lymphoma Foundation, where she also leads the charity’s marketing and communications efforts. She initially joined the FLF as the Individual Giving Manager in 2022 and was promoted to her current role in 2024. Rosie is dedicated to enhancing the value and duration of support from donors and engaging with our volunteers who organize fundraising events.

Prior to her time at FLF, Rosie worked at Marie Curie and Blind Veterans, gaining extensive experience in individual giving and donor engagement. Passionate about improving cancer treatments globally, she is committed to spreading the FLF message and ensuring the necessary funds are raised to find a cure. Rosie deeply values every donor, recognizing that the charity’s work is only possible thanks to their generosity and support.

Nicola James

Nicola has a background in clinical trial and operational research coordination, previously focusing on infectious diseases such as malaria and tuberculosis. In her previous role at Médecins Sans Frontières/Doctors Without Borders she worked on a successful clinical trial which revolutionised treatment for people with drug-resistant tuberculosis and is now being used worldwide.

Through her work, Nicola has specialised in community and patient engagement and involvement at an international level, having previously worked at the London School of Hygiene and Tropical Medicine, Mahidol-Oxford Tropical Medicine Research Unit and the International Organisation for Migration.

Nicola has joined the FLF team to support the development and implementation of FLF research and patient programmes. She feels passionate to contribute to accelerating translational research and is committed to collaborating with those most affected by research outcomes, ensuring that the patient perspective is meaningfully integrated into research.

Our advisors

Dr David Kennard Industry Advisor

David has worked across the pharmaceutical industry for three decades and has been advising the FLF since February 2019.

From 2017-2018, David advised Cancer Research UK on re-structuring and implementing change within the Commercial Partnerships division. He also headed up the Opportunity Sourcing and Translation group through formation and recruitment of a team of 15 practitioners. He led on elements of CRUK’s Innovation and Entrepreneurship agenda.

For 4 years previously, David was Senior Advisor within the Corporate Development group at Gilead Sciences. Dr Kennard was also VP, Strategic Alliances YM BioSciences Inc. prior to its acquisition by Gilead Sciences in February 2013. Before joining YM, he was CEO of NeuroTargets, and prior to that he was COO of SR Pharma Plc, a UK-based biotechnology company which developed therapeutic vaccines. He was also with GlaxoSmithKline in development and then strategic planning roles.

Dr Jessica Okosun Scientific Advisor

Jessica Okosun is Professor of Translational Cancer Research and Cancer Research UK Clinician Scientist at the Barts Cancer Institute, Queen Mary University of London.

She is a Consultant Haematologist at St Bartholomew’s Hospital, London UK specialising in lymphomas.

Her research interests are focused on understanding how lymphomas initiate, diversify and evolve, particularly follicular lymphoma in a bid to define novel biomarkers and improve treatment. She serves as a member of the UK’s National Cancer Research Institute (NCRI) Low Grade and High Grade Lymphoma subgroups. She also serves on a number of Scientific Advisory Committees. She chairs the Barts Cancer Centre’s Patient and Public Involvement Research Advisory Group. Jessica has been advising the FLF since February 2019.